BMS-986369 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-01-30 in 4mo
ESTIMATED |
READOUT
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986
Phase 1/2 · Relapsed or Refractory T-cell Lymphomas |
BMY BRISTOL MYERS SQUIBB CO | BMS-986369 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-10-02
Sponsor-projected date — can change
|